← Back to search
INSTITUTE FOR CLINICAL PHARMACODYNAMICS, INC.
Doing business as INSTITUTE FOR CLINICAL PHARMACODYNAMICS INC
SCHENECTADY, NY, 12305
UnclaimedClaim this profile (free)
Other Than Small Business
Prime contracting experience
4 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services Food and Drug Administration | BAA CONTRACT - DEVELOPMENT OF SUSCEPTIBILITY GUIDANCE FOR DAPTOMYCIN AND ENTEROCOCCUS SPECIES USING PHARMACOMETRIC APPROACHES | — | $325,000 | Jun 30, 2026 | Aug 1, 2026 – Jul 31, 2027 |
| Prime | Department of Health and Human Services Food and Drug Administration | THIS IS A FIRM FIXED PRICE CONTRACT FOR DEVELOPMENT OF MODERNIZED SUSCEPTIBILITY GUIDANCE FOR AMPICILLIN AND VANCOMYCIN FOR ENTEROCOCCUS SPECIES USING PHARMACOMETRIC APPROACHES | — | $263,016 | Jun 24, 2025 | Sep 18, 2023 – Jun 24, 2025 |
| Prime | Department of Health and Human Services Food and Drug Administration | A STUDY IN THE "DEVELOPMENT OF MODERNIZED SUSCEPTIBILITY GUIDANCE FOR ORAL SULFAMETHOXAZOLE-TRIMETHOPRIM USING PHARMACOMETRICS APPROACHES" BAA PMWP #195 | — | $291,142 | Nov 16, 2022 | Sep 22, 2022 – Sep 29, 2023 |
| Prime | Department of Health and Human Services Food and Drug Administration | COMBATTING ANTIBIOTIC RESISTANT BACTERIA (CARB) PROGRAM | — | $291,618 | Sep 21, 2022 | Sep 21, 2022 – Sep 29, 2023 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Subcontracting experience
2 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | ICPD€„¢S PARTICIPATION IN THIS PROJECT TO DEFINE THE IN VIVO MODEL ENDPOINT FOR HUMANIZED POSACONAZOLE AND 10 CLINICAL SUSCEPTIBLE AND -RESISTANT A. FUMIGATUS ISOLATES, PK-PD CHARACTERIZATION OF EACH ANTIFUNGAL AGENT USING THE VALIDATED MOUSE-LUNG MODEL AND 10 A. FUMIGATUS STRAINS, AND IDENTIFY CANDIDATE STIC FOR EACH AGENT, WHERE ANIMAL MODEL-DERIVED PK/PD RELATIONSHIPS AND PK MODEL-DERIVED HUMAN EXPOSURES ARE INTEGRATED THROUGH SIMULATION IN THE CONTEXT OF CONTEMPORARY MIC DISTRIBUTION DATA. 0000003317 Parent award context Parent award agency: Department of Health and Human Services · Food and Drug Administration Parent award NAICS: 541714 Parent award performance state: WI Parent award description: CDER-BAA-COMBATTING ANTIBIOTIC RESISTANT BACTERIA (CARB) PROGRAM STUDY View parent award on USAspending | — | $173,800 | Nov 21, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | THIS WORK REVISITS STIC FOR COMMONLY PRESCRIBED ORAL CEPHALOSPORINS THAT ARE NOT SUPPORTED BY A MODERN PHARMACOMETRIC APPROACH. OUR GOAL IS TO IMPROVE STIC FOR €œOLDER€Ͽ½ ORAL AGENTS THAT ARE BEING INCREASINGLY RECOMMENDED FOR TREATMENT OF SEVERE BACTERIAL INFECTIONS IN ORDER TO IMPROVE CLINICIAN TREATMENT DECISIONS FOR THIS EMERGING TREATMENT TREND AND MEET THE FAR DEFINITION FOR DEVELOPMENT. THE OBJECTIVES INCLUDE: 1] CONTEMPORARY CHARACTERIZATION OF MIC DISTRIBUTION FOR TREATMENT GUIDELINE-RECOMMENDED ORAL CEPHALOSPORINS AGENTS AGAINST E. COLI AND S. AUREUS. 2] PK/PD CHARACTERIZATION OF RECOMMENDED ANTIMICROBIAL AGENTS AGAINST E. COLI AND S. AUREUS USING A VALIDATED MOUSE-THIGH MODEL. 3] IDENTIFY CANDIDATE STIC FOR EACH ANTIMICROBIAL AGENT, WHERE ANIMAL MODEL-DERIVED PK-PD RELATIONSHIPS AND PK MODEL-DERIVED HUMAN EXPOSURES ARE INTEGRATED THROUGH MONTE CARLO SIMULATION IN THE CONTEXT OF CONTEMPORARY MIC DISTRIBUTION DATA. AS THESE OBJECTIVES ARE TOWARDS IMPROVING AND ADVANCING AN EXISTING TECHNOLOGY THAT PROPOSAL MEETS THE DEFINITION OF DEVELOPMENT. THE PROPOSAL IS SPECIFICALLY RESPONSIVE TO 2.4.4: ADVANCE THE SCIENCE OF ANTIBACTERIAL DRUG SUSCEPTIBILITY TESTING TO ENSURE THAT UP TO DATE SUSCEPTIBILITY TESTING CRITERIA (BREAKPOINTS) ARE AVAILABLE FOR PATIENT CARE AND ANTIMICROBIAL STEWARDSHIP). 0000002846 Parent award context Parent award agency: Department of Health and Human Services · Food and Drug Administration Parent award NAICS: 541714 Parent award performance state: MD Parent award description: DEVELOPMENT OF MODERNIZED SUSCEPTIBILITY GUIDANCE FOR ORAL CEPHALOSPORIN ANTIMICROBIAL AGENTS USING PHARMACOMETRIC APPROACHES; BAA PMWP #186 View parent award on USAspending | — | $107,630 | Apr 20, 2023 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.